DRI Healthcare Comments on Juvmo’s (tavapadon) FDA Approval

TORONTO, Sept. 28, 2026 /CNW/ — DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI Healthcare”) today commented on the U.S. Food and Drug Administration’s (“FDA”) recently announced approval of Juvmo (tavapadon) for the treatment of motor symptoms that occur in Parkinson’s disease. Juvmo (tavapadon) is a novel selective dopamine D1/D5 receptor partial agonist developed as a once-daily oral treatment for Parkinson’s disease, for use both with and without levodopa.

DRI Healthcare previously announced that it has entered into certain purchase agreements to acquire certain royalty participation rights in U.S. net sales of Juvmo (tavapadon) from funds managed by Bain Capital and NovaQuest Capital Management. DRI Healthcare will pay an aggregate purchase price of US$316 million at closing, funded through a combination of cash on hand and borrowings under its credit facility. Closing is subject to the satisfaction of certain customary closing conditions and is expected to occur on September 29, 2026.

Transaction Terms

Under the terms of the purchase agreements, DRI Healthcare will be entitled to four annual fixed payments of US$23.4 million on or before each of the first four anniversaries of FDA approval, commencing on September 25, 2027. DRI Healthcare will also be entitled to receive tiered royalty payments on annual U.S. net sales of Juvmo (tavapadon), at combined tiered, mid-single digit to low-double digit royalty rates, and certain sales milestone payments upon first reaching certain cumulative U.S. net sales thresholds. Aggregate receipts to DRI Healthcare under the acquired payment rights will be subject to a contractual hard cap of US$437.5 million.

About Parkinson’s Disease

Parkinson’s disease (PD) is a progressive neurological and chronic neurological disorder affecting more than 10 million people globally. It is caused by the loss of dopamine-producing neurons in a region of the brain called the substantia nigra. By the time motor symptoms become apparent, 60 to 80 percent of those neurons have already been lost. PD presents with both motor and non-motor symptoms. Motor symptoms include tremor, limb rigidity, slowness of movement, and problems with balance and gait. Non-motor symptoms, which patients often find equally debilitating, include depression, anxiety, sleep disorders, cognitive changes and loss of smell. Symptoms progress at different rates and vary from person to person. There is no cure, and while treatments can improve quality of life, none has been shown to slow or halt disease progression.

About DRI Healthcare

DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Since our founding in 1989, we have deployed more than $3.0 billion, acquiring more than 75 royalties on 50-plus drugs, including Eylea, Keytruda, Lumvoa, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. DRI Healthcare’s units are listed and trade on the TSX in Canadian dollars under the symbol “DHT.UN” and in U.S. dollars under the symbol “DHT.U”. To learn more, visit drihealthcare.com or follow us on LinkedIn.

Caution concerning forward-looking statements

This news release may contain forward-looking information within the meaning of applicable securities legislation including statements regarding the expected closing of the transaction, including satisfaction of closing conditions; the payment of the purchase price on closing; DRI Healthcare’s acquisition of royalty participation rights in Juvmo (tavapadon), the potential for commercialization of Juvmo (tavapadon) and future U.S. net sales; and the potential receipt by DRI Healthcare of royalties, milestone payments and fixed payments in respect of Juvmo (tavapadon). Forward-looking information can generally be identified by the use of words such as “expect”, “continue”, “anticipate”, “intend”, “aim”, “plan”, “believe”, “budget”, “estimate”, “forecast”, “foresee”, “close to”, “target” or negative versions thereof and similar expressions. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond DRI Healthcare’s control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information, including, without limitation: the uncertainty of commercial success of Juvmo (tavapadon); competition from other products; and other risks and uncertainties disclosed in DRI Healthcare’s most recent annual information form and under “Risk Factors” in DRI Healthcare’s Management’s Discussion and Analysis. You should not put undue reliance on forward-looking statements. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do occur, the actual results, performance or achievements of DRI Healthcare could differ materially from the results expressed in, or implied by, any forward-looking statements. All forward-looking information in this news release speaks as of the date of this news release. DRI Healthcare does not undertake to update any such forward-looking information whether as a result of new information, future events or otherwise except as required by law. Additional information about these assumptions and risks and uncertainties is contained in DRI Healthcare’s filings with securities regulators, including its latest annual information form and Management’s Discussion and Analysis. These filings are also available at DRI Healthcare’s website at drihealthcare.com/investors.

For further information, please contact:

Zaheed Mawani

Chief Financial Officer

[email protected]

SOURCE DRI Healthcare Trust